UBS Group Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $2.20

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective reduced by analysts at UBS Group from $5.00 to $2.20 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target indicates a potential upside of 16.40% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Finally, Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $8.58.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.89 on Tuesday. Zentalis Pharmaceuticals has a fifty-two week low of $1.76 and a fifty-two week high of $18.07. The business has a 50-day moving average of $3.00 and a 200 day moving average of $3.30. The firm has a market cap of $134.68 million, a P/E ratio of -0.76 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, research analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Barclays PLC boosted its position in shares of Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after buying an additional 353,384 shares in the last quarter. Verition Fund Management LLC grew its position in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after buying an additional 951,500 shares during the period. Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares in the last quarter. Finally, Primecap Management Co. CA increased its stake in shares of Zentalis Pharmaceuticals by 21.6% during the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.